Navigation Links
Organovo Announces Two Issued Patents, First Company Patent and Key Founder Patent
Date:7/9/2012

SAN DIEGO, July 9, 2012 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQB: ONVO), a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology, today announced the receipt of a patent based on its first patent application as well as the issuance of a key founder patent.   Organovo is focused on developing bioprinting across a broad array of cell types to create functional 3D tissues that can recapitulate in vivo biology for human disease research, drug discovery and development, toxicology testing and, eventually, as therapies.

The Intellectual Property Office of the United Kingdom issued the Company a patent GB2478801, entitled "Multilayered Vascular Tubes."  This is Organovo's first issued patent and represents the issuance of a patent from the Company's first patent application, which was submitted in May 2010. 

Organovo further noted that a key patent representing one of its core bioprinting technologies has issued. Patent number U.S. 8,143,055, entitled "Self-assembling multicellular bodies and methods of producing a three-dimensional biological structure using the same," was issued and assigned to the University of Missouri.  Under its agreements with the University of Missouri, Organovo holds the exclusive license in all fields to multiple patent families, including this issued patent and future continuation patents derived from the same application.

"The recent issuance of multiple bioprinting patents highlights the innovation of our bioprinting technologies," commented Keith Murphy, chairman and chief executive officer of Organovo.  "The issuance of the first patent from the family of patent applications filed by our scientific founder, Prof. Gabor Forgacs while at the University of Missouri, validates his technology and reinforces the foundation of our patent protection. We are pleased to have obtained these foundational patents as part of our early lead in three-dimensional biology, and we will continue to focus on growing our patent portfolio to support the use of 3D bioprinting for human disease research, drug discovery and development, toxicology testing and tissue therapies."

The issuance of the "Multilayered Vascular Tubes" patent provides protection on an application-specific basis that is independent of method and is part of Organovo's larger intellectual property strategy to create application-specific protection and to obtain coverage in multiple countries.  In addition to the patents described above, Organovo's intellectual property portfolio consists of exclusive licenses to two patent applications from the University of Missouri, one issued patent from Clemson University, and a number of Organovo patent applications pending in the U.S. and internationally, and will pursue the "Multilayered Vascular Tubes" patent in the United States.

About Organovo Holdings, Inc. Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. The company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types. Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine. Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development. Organovo's bioprinting technology can also be developed to create surgical tissues as direct therapy. Organovo leads the way in solving complex medical research problems and building the future of medicine. For more information, please visit http://www.organovo.com.

Safe Harbor Statement Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our most recent Quarterly Report on Form 10-Q. We do not undertake to update these forward-looking statements made by us.  


'/>"/>
SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Organovo Holdings Appoints James T. Glover to Board of Directors
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
4. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
5. Misonix Announces New Distribution Agreement For Panama
6. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
9. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
10. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
11. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... The Bio Supply Management Alliance (BSMA) has ... and the Biomedical Manufacturing Network to advance ... California by providing a platform for ... workforce development. The primary focus of this alliance is ... well as small and mid-sized biomedical companies. ...
(Date:6/10/2017)... , June 9, 2017  Shane K. Burchfield, DPM, is recognized ... excellence as a Podiatrist in Alabama . ... Family First Foot Care. He brings over 20 years of experience, ... management and healthcare, to his role. ... Care, PC is pleased to welcome you to his ...
(Date:6/8/2017)... Texas , June 8, 2017 /PRNewswire/ ... a leading developer and manufacturer of diagnostic ... announced today that Cressey & Company LP ... firm, has completed a growth-focused investment in ... a majority ownership position from selling shareholder, ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... 2017 , ... The Pennsylvania Athletic Trainers’ Society’s (PATS) Annual ... Convention Center on June 8-10. The weekend consisted of many educational presentations, ... scholarship presentations, and professional networking. , On Friday June 9th, PATS hosted ...
(Date:6/23/2017)... RI (PRWEB) , ... June 23, 2017 , ... ... Care Network today announced the launch of Care Management Alerts and Dashboards, an ... 140,000 patients throughout Rhode Island. , RIQI’s Care Management Alerts and Dashboards provide ...
(Date:6/23/2017)... ... June 24, 2017 , ... Studies show evidence that carotenoids and ... of visual loss in these patients. , But how often do ophthalmologists and optometrists ... to patients at risk of or with early symptoms of AMD? A study ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference ... to read it, and some people don't like it at all. FindaTopDoc took a ... found: , Erotic literature can give readers a taste of their deepest, darkest fantasies ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia ... Sept. 18 to 20. , The two-day conference is focused on advancing scientific ... of improving patients’ lives and eliminating racial breast cancer-related disparities. The conference theme ...
Breaking Medicine News(10 mins):